Sign In
Buy XERS
$7.20
+0.300 (+4.35%)
At Close: Jun 23, 2026
Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®
04:39pm, Thursday, 11'th Jun 2026
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient liv
Xeris Biopharma Announces Private Exchange of Convertible Notes
08:00am, Thursday, 11'th Jun 2026
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing
Xeris Biopharma Announces Private Exchange of Convertible Notes
07:00am, Thursday, 11'th Jun 2026
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod
Xeris Looks Ridiculously Cheap If Growth Forecasts Are Even Halfway Right
11:31pm, Saturday, 30'th May 2026
Xeris Biopharma has delivered another year of significant revenue growth, signaling a pivotal moment in its trajectory. XERS has reached an inflection point, indicating a shift in its business momentu
Xeris Biopharma Q1 Earnings Call Highlights
04:07am, Saturday, 09'th May 2026
Xeris Biopharma NASDAQ: XERS reported a sharp increase in first-quarter 2026 revenue and raised the low end of its full-year revenue outlook, citing strong demand for RECORLEV and continued execution
Xeris Biopharma Holdings, Inc. (XERS) Q1 2026 Earnings Call Transcript
01:41pm, Thursday, 07'th May 2026
Xeris Biopharma Holdings, Inc. (XERS) Q1 2026 Earnings Call Transcript
Xeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
10:31am, Thursday, 07'th May 2026
The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street
Xeris Biopharma Reports First Quarter 2026 Financial Results
07:00am, Thursday, 07'th May 2026
CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of “Moderate Buy” from Analysts
02:12am, Friday, 24'th Apr 2026
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) has earned an average rating of "Moderate Buy" from the seven research firms that are currently covering the firm, MarketBeat reports. T
Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026
07:30am, Thursday, 23'rd Apr 2026
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod
Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock
05:57am, Sunday, 05'th Apr 2026
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the company's stock in a transaction dated Wednesday, April 1st. The stock was sold at an avera
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:15pm, Friday, 03'rd Apr 2026
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod
Xeris Biopharma Holdings, Inc. (XERS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
01:32pm, Wednesday, 11'th Mar 2026
Xeris Biopharma Holdings, Inc. (XERS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript
10:57am, Monday, 02'nd Mar 2026
Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript
Xeris Biopharma (XERS) Reports Q4 Earnings: What Key Metrics Have to Say
10:30am, Monday, 02'nd Mar 2026
The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Stre
